Anant Labs

Sunitinib

CAS 557795-19-4

Overview

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor that was approved by the FDA for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor on January 26, 2006

Anant Labs manufacture and furnish high quality Sunitinib impurities for global markets. Our Sunitinib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.

Active Pharmaceutical Ingredient